Abstracts tagged "Sjogren’s syndrome and neonatal lupus"

Abstract Number: 86 • 2015 ACR/ARHP Annual Meeting
Auxilin Is a Novel Susceptibility Gene for Congenital Heart Block Modulating Cardiac Function
Sabrina Meisgen¹, Malin Hedlund¹, Aurélie Ambrosi¹, Lasse Folkersen², Vijole Dzikaite-Ottosson³, Bo Ding¹, Linn Strandberg⁴, Luca Biavati⁴, Daniel Ramsköld⁵, David Forsberg¹, Lisa Bergin¹, Sabrina Ruhrmann¹, The Swedish Congenital Heart Block Study Group¹, Robert M. Hamilton⁶, Anders Franco-Cereceda¹, Anders Hamsten¹, Tomas Olsson⁷, Lois Greene⁸, Per Eriksson¹, Kristina Gemzell-Danielsson¹, Stina Salomonsson¹, Vijay K. Kuchroo⁹, Eric Herlenius¹, Ingrid Kockum⁷, Sven-Erik Sonesson¹ and Marie Wahren-Herlenius¹⁰, ¹Karolinska Institutet, Stockholm, Sweden, ²Technical University of Denmark, Copenhagen, Denmark, ³Department of Medicine, Rheumatology Unit, Centre for Molecular Medicine (CMM), Karolinska Institutet, Stockholm, Sweden, ⁴Hospital for Sick Children Toronto, Toronto, ON, Canada, ⁵Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁶Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁷Neuroimmunology, Department of Clinical Neurosciences, Karolinska Institutet, Stockholm, Sweden, ⁸National Heart, Lung and Blood Institute, Bethesda, MD, ⁹Center of Neurological Disease, Harvard Medical School, Boston, MA, ¹⁰Department of medicine, Rheumatology unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Congenital heart block (CHB) may affect children of women with anti-Ro/SSA and anti-La/SSB autoantibodies. The most recognized manifestation of CHB is an atrioventricular (AV)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].